2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

Overview

This is a single-center, randomized, double-blind, placebo-controlled, sequential, multiple-dose study. The study will be conducted in two parts: Part A (6 cohorts of healthy adults receiving evening dosing) and Part B (one cohort of elderly adults receiving evening dosing).

Full Title of Study: “A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of E2006 in Healthy Adult and Elderly Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: May 2013

Interventions

  • Drug: E2006
    • Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
  • Drug: Placebo comparator
    • E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo comparator
  • Experimental: E2006

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of Adverse events (AEs)
    • Time Frame: 28 days

Secondary Measures

  • Plasma concentrations of E2006
    • Time Frame: Part A up to 288 hours postdose; Part B: up to 324 hours postdose

Participating in This Clinical Trial

Included:

  • Healthy males or females, ages 18 to 55 years (Part A) or 65 to 80 years (Part B) – Who report typical time in bed 7.5 to 9 hours – Who report typical bedtime 22:00 – 24:00 and typical wake time 06:00 – 08:00 – Who report typical sleep latency of <= 30 minutes – All females must be of non-childbearing potential, or subjects who have been sterilized surgically or who are otherwise proven sterile. Females must have a negative serum beta-human chorionic gonadotropin (Beta-hCG) test result at Screening and a negative urine pregnancy test at Baseline. – Body mass index BMI > 18 and 32 kg/m2 at Screening Excluded: – Performed shift work within 2 weeks prior to Screening – Had taken a flight across three or more time zones in the 7 days prior to Screening – Female subjects who are nursing – With a history of gastrointestinal surgery (hepatectomy, nephrectomy, digestive organ resection, etc.) that may affect PK profile of E2006 – With a known history of clinically significant drug or food allergies or presently experiencing significant seasonal allergy – Hypersensitivity to the study drug or any of the excipients

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Eisai Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Dohwa Kim, Principal Investigator, Parexel

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.